Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Assets (2016 - 2026)

Catalyst Pharmaceuticals filings provide 17 years of Assets readings, the most recent being $1.1 billion for Q1 2026.

  • On a quarterly basis, Assets rose 26.27% to $1.1 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $1.1 billion, a 26.27% increase, with the full-year FY2025 number at $1.1 billion, up 29.66% from a year prior.
  • Assets hit $1.1 billion in Q1 2026 for Catalyst Pharmaceuticals, up from $1.1 billion in the prior quarter.
  • In the past five years, Assets ranged from a high of $1.1 billion in Q1 2026 to a low of $247.0 million in Q1 2022.
  • Median Assets over the past 5 years was $646.7 million (2024), compared with a mean of $654.0 million.
  • Biggest five-year swings in Assets: increased 24.04% in 2023 and later surged 86.83% in 2024.
  • Catalyst Pharmaceuticals' Assets stood at $375.6 million in 2022, then rose by 25.15% to $470.1 million in 2023, then surged by 81.11% to $851.4 million in 2024, then rose by 29.66% to $1.1 billion in 2025, then grew by 3.95% to $1.1 billion in 2026.
  • The last three reported values for Assets were $1.1 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.1 billion (Q3 2025) per Business Quant data.